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ABSTRACT
Introduction Grades 2 and 3 gliomas (G2/3 gliomas),
when combined, are the second largest group of
malignant brain tumours in adults. The outcomes for G2/3
gliomas at progression approach the dismal outcomes
for glioblastoma (GBM), yet there is a paucity of trials
for Australian patients with relapsed G2/3 gliomas
compared with patients with GBM. LUMOS will be a pilot
umbrella study for patients with relapsed G2/3 gliomas
that aims to match patients to targeted therapies based
on molecular screening with contemporaneous tumour
tissue. Participants in whom no actionable or no druggable
mutation is found, or in whom the matching drug is not
available, will form a comparator arm and receive standard
of care chemotherapy. The objective of the LUMOS trial is
to assess the feasibility of this approach in a multicentre
study across five sites in Australia, with a view to
establishing a national molecular screening platform for
patient treatment guided by the mutational analysis of
contemporaneous tissue biopsies
Methods and analysis This study will be a multicentre
pilot study enrolling patients with recurrent grade
2/3 gliomas that have previously been treated with
radiotherapy and chemotherapy at diagnosis or at first
relapse. Contemporaneous tumour tissue at the time of
first relapse, defined as tissue obtained within 6 months
of relapse and without subsequent intervening therapy,
will be obtained from patients. Molecular screening will
be performed by targeted next-generation sequencing at
the reference laboratory (PathWest, Perth, Australia). RNA
and DNA will be extracted from representative formalin-
fixed paraffin embedded tissue scrolls or microdissected
from sections on glass slides tissue sections following a
review of the histology by pathologists. Extracted nucleic
acid will be quantified by Qubit Fluorometric Quantitation
(Thermo Fisher Scientific). Library preparation and
targeted capture will be performed using the TruSight
Tumor 170 (TST170) kit and samples sequenced on
NextSeq 550 (Illumina) using NextSeq V.2.5 hi output
reagents, according to the manufacturer’s instructions.

Strengths and limitations of this study
► This study will prospectively investigate the fea-

sibility and utility of contemporaneous molecular
profiling in patients with relapsed grades 2 and 3
gliomas to identify targetable mutations and potential matched drugs.
► This pilot study will also establish the feasibility of
integrating multidisciplinary discussion of individual
patients into tumour sequencing workflows, supporting a larger clinical trial.
► A molecular tumour advisory panel consisting of a
multidisciplinary committee with neuro-
oncology
expertise will provide the most appropriate treatment recommendations, tailored to drug availability
and eliminating superfluous information.
► Profiling of tissue at diagnosis and relapse will provide additional information about molecular evolution that occurs over time in lower grade glioma.
Data analysis will be performed using the Illumina
BaseSpace TST170 app v1.02 and a custom tertiary
pipeline, implemented within the Clinical Genomics
Workspace software platform from PierianDx (also refer
to section 3.2). Primary outcomes for the study will
be the number of patients enrolled and the number of
patients who complete molecular screening. Secondary
outcomes will include the proportion of screened patients
enrolled; proportion of patients who complete molecular
screening; the turn-around time of molecular screening;
and the value of a brain tumour specific multi-disciplinary
tumour board, called the molecular tumour advisory panel
as measured by the proportion of patients in whom the
treatment recommendation was refined compared with
the recommendations from the automated bioinformatics
platform of the reference laboratory testing.
Ethics and dissemination The study was approved by
the lead Human Research Ethics Committee of the Sydney
Local Health District: Protocol No. X19-0383. The study
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will be conducted in accordance with the principles of the Declaration
of Helsinki 2013, guidelines for Good Clinical Practice and the National
Health and Medical Research Council National Statement on Ethical
Conduct in Human Research (2007, updated 2018 and as amended
periodically). Results will be disseminated using a range of media
channels including newsletters, social media, scientific conferences and
peer-reviewed publications.
Trial registration number ACTRN12620000087954; Pre-results.

INTRODUCTION
Primary brain tumours are rare cancers, ranking as the
15th most common cancer by incidence in Australia in
2017.1 Despite their relative rarity, brain tumours have
a large impact on mortality and morbidity, particularly
in adolescents and young adult (AYA) patients aged
15–24 years, for whom they represent the leading cause
of cancer related mortality. The most common type of
primary brain tumour (~45% of primary brain tumours)
is grade 4 glioma (glioblastoma), which is associated with
the shortest overall survival (OS).
Grades 2 and 3 gliomas (G2/3 gliomas) are the second
largest group of malignant brain tumours in adults,
making up approximately 17% of all primary brain
tumours.1 2 They consist of G2 gliomas (low grade) and G3

gliomas (intermediate grade). The latter group (G3) have
historically been classified together with high grade gliomas,
some colloquial reference to them as ‘intermediate’ grade
occurs given their distinct natural history and treatment
compared with grade 4 gliomas (high grade).3 The recently
revised WHO CNS5 classification would upgrade some histological G2/3 gliomas tograde 4, based on their molecular
characteristics, giving them an integrated diagnosis of glioblastoma.4 The historical definition of G2/3 gliomas has
been used to enable comparison with already completed
studies. Hereafter, we will refer to the G2 and G3 gliomas
collectively as ‘lower grade’ gliomas for the sake of brevity.
Adjuvant treatment of newly diagnosed high risk G2 gliomas
with radiotherapy and chemotherapy results in significant
improvements in OS5 while adjuvant radiotherapy and
chemotherapy improves survival in high-grade glioma such
as anaplastic oligodendroglioma6 or glioblastoma7 (table 1).
For G2 gliomas as a whole, the addition of procarbazine,
CCNU (lomustine) and vincristine (PCV) chemotherapy
to radiotherapy improves the median OS from 7.8 to 13.3
years (HR 0.59).5 Oligodendrogliomas are particularly sensitive to chemotherapy and the addition of adjuvant PCV to
RT alone in G3 oligodendrogliomas results in a significant

Table 1 Standard adjuvant treatment and survival of glioma subtypes at diagnosis

Nomenclature (WHO 2016)
Glioblastoma, IDH-wildtype WHO
(2016) grade IV
Anaplastic astrocytoma, IDH-
wildtype, WHO (2016) grade III
Anaplastic astrocytoma, IDH-
mutant, WHO (2016) grade III

Overlapping
nomenclature (WHO
2021)
Glioblastoma, IDH –
wildtype, CNS WHO
grade 4
Glioblastoma, IDH –
wildtype, CNS WHO
grade 4

Molecular
characteristics
IDH wild-type

IDH wild-type

Astrocytoma, IDH-
IDH mutated
mutant, CNS WHO grade 1p19q non-co-
3
deleted

Anaplastic oligodendroglioma,
Oligodendroglioma,
IDH mutated
IDH-mutant and 1p/19q codeleted, IDH-mutant, and 1p/19q 1p19q co-deleted
WHO (2016) grade III
co-deleted, CNS WHO
grade 3

Median
First line treatment
overall
following maximal safe survival from
resection
diagnosis
Chemoradiotherapy
with subsequent
temozolomide
Chemoradiotherapy
with subsequent
temozolomide

~15 months7

Radiotherapy
with subsequent
temozolomide

~5 years26

Radiotherapy then
PCV chemotherapy

>11 years26

~20 months26

Diffuse astrocytoma, IDH-wildtype, Glioblastoma, IDH–
WHO (2016) grade II
wildtype, CNS WHO
grade 4 (in some cases)

IDH wild-type

Consider radiotherapy
followed by
chemotherapy

~5 years26

Diffuse astrocytoma, IDH-mutant,
WHO (2016) grade II (high risk)

IDH mutated
1p19q non-co-
deleted
IDH mutated
1p19q co-deleted

Radiotherapy then
PCV chemotherapy

~8 years26

Radiotherapy then
PCV chemotherapy

>12 years26

Astrocytoma, IDH–
mutant, CNS WHO grade
2
Oligodendroglioma, IDH-mutant
Oligodendroglioma,
and 1p/19q codeleted, WHO (2016) IDH-mutant and 1p/19q
grade II (high risk)
co-deleted, CNS WHO
grade 2

High-risk features include ≥3 variables; age ≥40, astrocytoma histology, tumours ≥6 cm, tumour crossing midline or preoperative neurological
deficits (not seizure).27 A comparison with the updated WHO 2021 CNS5 classification is made although this was not published at the time of
study initiation.4 IDH-wild-type grade 3 astrocytoma is frequently associated with molecular features of glioblastoma.5 28
CNS, Central nervous system; IDH, Isocitrate dehydrogenase; PCV, procarbazine, CCNU (lomustine), vincristine.
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Table 2 Summary of benefit from systemic therapy of G2/3 gliomas at relapse
G2 gliomas

G3 gliomas

Mixed G2 and G3

Post-radiotherapy but no prior systemic therapy
RR: 27%29
RR: 44%–63%8 9
Chemo8–10
29
mPFS:10mo
mPFS: 7-10mo8 9
11
PFS6: 67%
PFS6: N/A
PFS12: N/A
PFS12:N/A
mOS: 14mo29
mOS: 16-20mo8 9
OS12: N/A
OS12: N/A
OS24: N/A
OS24: N/A

RR: 54%11
mPFS: 8mo11
PFS6: 67%11
PFS12:25%11
mOS: 14mo11
OS12: 60%11
OS24: 23%11

Pre-treated with radiotherapy and systemic therapy
30–32

Chemo

33

RR: 47%*
mPFS: 10mo33*
PFS6: 76%33
PFS12: 39%33*
mOS: N/A
OS6 N/A

Targeted ± Chemo33–37 RR: 036*
mPFS: 11mo*36
PFS6: N/A
PFS12: 39%36*
mOS: N/A
OS6 94%36*
Bevacizumab
monotherapy38 39

N/A

Comments:

Chemo: TMZ,10 12 33
hydroxyurea36
Targeted: erlotinib,37
imatinib36

All three groups
Median (range)
 
RR: 49% (27–63)
mPFS: 9mo (7–10)
mOS: 15mo (14–20)

 
30–32

RR:13%–23%
mPFS: 4-8mo30–32
PFS6: 30%–40%30 31
PFS12: 5%–8%30 31
mOS: 7-19mo30 31
OS12: 23%31

N/A

RR: 0-1034 37
mPFS: 2-3mo34 37
PFS6: 24%34
PFS12: 14%34
mOS: 2-8mo34 37
OS6: N/A

RR: 0%–8%35 36
mPFS: 2–11mo35 36
PFS6: 15%35
PFS12: N/A
mOS: 7mo35
OS6: 20%35

RR: 0% (0–10)
mPFS: 3mo (2–11)
PFS6 20% (15–24)
mOS: 7mo (2–8)

RR: 43%–64%38 39
mPFS: 3-7mo38 39
PFS6: 21%38
mOS: 9–12 mo38 39
OS6: 76%39
OS12: 36%39
Chemo: TMZ,8 PCV,9
cyclophosphamide,32 irinotecan,31
paclitaxel,30 hydroxyurea34
Targeted: imatinib34

N/A

RR: 54% (0–10)
mPFS: 5mo (3–7)
mOS: 11mo (9–12)

Chemo: CCNU,35
hydroxyurea36
Targeted: sunitinib,35
imatinib36

 

RR: 23% (13–47)
mPFS: 6mo (4–10)
PFS6: 40% (30–76)
mOS: 8 mo (7–19)

*These studies contained approximately two-thirds patients without prior systemic therapy.
CCNU, Lomustine; mOS, median overall survival; mPFS, median progression-free survival; N/A, not available; PCV, procarbazine, CCNU and
vincristine; RR, response rate; TMZ, temozolomide.

improvement in median OS from 7.3 years to 14.7 years (HR
0.59). The definition of oligodendroglioma in clinical trials
has evolved over time from a histological to molecular definition based on 1p/19q co-deletion. For patients with G3
anaplastic glioma without a 1p/19q deletion, the addition
of adjuvant temozolomide (TMZ) results in an even greater
relative OS improvement.
Despite the relatively favourable overall prognosis
of newly diagnosed G2/3 gliomas, the outcomes for
G2/3 gliomas at the time of relapse following standard
treatment approach those of glioblastoma; the median
progression-free survival (PFS) is 9 months and median OS
15 months.8–11 Furthermore, the limited data on patients
with relapse suggest that OS is minimally affected by the
histology at diagnosis (table 2). Patients with relapsed
G2/3 gliomas can experience highly symptomatic
relapses, characterised by seizures together with cognitive
and functional impairment.12 In this setting, there is no
accepted standard of care treatment although common
Kong BY, et al. BMJ Open 2021;11:e054075. doi:10.1136/bmjopen-2021-054075

chemotherapeutic regimens that are used include PCV,
TMZ, CCNU/carmustine or other platinum-based regimens depending on prior chemotherapy exposure.
Rationale for umbrella trial design
LUMOS is an umbrella study that will screen G2/3 glioma
patients with relapsed disease for actionable tumour mutations that are matched to targeted drugs. Given the diversity of targets in G2/3 gliomas (table 3), the umbrella trial
design was chosen to efficiently test a range of targeted
drugs. The requirement to screen patients who have
contemporaneous tissue available will ensure that molecular targets identified during screening will accurately
reflect the expected targets within the tumour at the time
of receiving treatment. This study design will minimise
the possibility that genomic or epigenetic evolution has
occurred between the time of initial biopsy and disease
relapse, thus rendering targeted therapies ineffective.13
3

BMJ Open: first published as 10.1136/bmjopen-2021-054075 on 30 December 2021. Downloaded from http://bmjopen.bmj.com/ on February 3, 2022 at Jackson Laboratory Library. Protected
by copyright.

Open access

Table 3 Potential drug therapies by mutation status in the LUMOS study
Gene mutation

IDH mutated, 1 p/19q
co-deleted

IDH mutated,
1 p/19q intact IDH wild-type Potential targeted drugs

IDH mutation

100%

100%

0%

BRAF amplification

39%40

2%40

17%40

Multiple including IDH inhibitors,
IDH vaccines, PARP inhibitors,
immunotherapy
RAF inhibitors, MEK inhibitors

2%–9%17 41

PI3K inhibitors

17

PI3K inhibitors

17 41

41

PIK3CA mutation

4%–20%

PIK3R1 mutation

9%

17

Occasional

EGFR amplification or
mutation

6%

41

41

BRAF V600E mutation

1%–5%42

PTEN inactivating mutation 2%

41

5%

17

Rare

17 41

15%

27%–89%

EGFR inhibitors or EGFR ADCs

0%42

0%17

BRAF inhibitors, MEK inhibitors

41

17 41

0%

20%–23%

PI3K inhibitors

PDGFRA amplification

~1%17

0-1617

0%–28%17

Multi-kinase inhibitors that include
PDGFR

CDK4 amplification

Rare17

Rare17

7%17

CDK4/6 inhibitors

0%

17

FGFR3 mutations and
fusions

0%

17

TRK Fusions
Total actionable mutations

Occasional43
62%–82%*

MDM4 amplification

17

17

Rare

13%

17

17

MDM inhibitors

0%

~10%

FGFR inhibitors

N/A
22%–38%*

N/A
Up to 89%*

TRK inhibitors
 

*Excluding IDH mutation itself.
ADC, antibody drug conjugate; EGFR, Epidermal growth factor receptor; FGFR, Fibroblast growth factor receptor; IDH, Isocitrate
dehydrogenase; MDM, Murine double minute; MEK, MAP kinase or ERK kinase; N/A, not available; PARP, Poly ADP ribose polymerase;
PDGFR, Platelet-derived growth factor receptor; TRK, Tropomyosin receptor kinase.

Given the poor prognosis of patients with progressive
or recurrent tumours, the better tolerability of targeted
agents over chemotherapy and the potential to discover
clinical activity of existing drugs in novel indications, the
LUMOS study design is expected to be attractive to both
patients and clinicians alike.
Feasibility and role of reresection at relapse for grade 2/3
gliomas
Reresection of tumour at the time of disease relapse is
considered feasible in the majority of patients with recurrent lower grade gliomas.14 In previous studies performed
prior to the routine use of post-operative adjuvant therapy
at initial diagnosis, gross total resection was achieved in up
to 50% of patients and the addition of adjuvant therapy
led to a significant improvement in PFS compared with
surgery alone.15
Pathological information gleaned from reresection
of tumour of an individual patient reveals that tumour
biology is significantly altered in recurrent tumours due
to clonal selective pressures generated by current therapies,13 with transformation to higher grade gliomas
(grade 3 or 4) occurring in 25% of cases. Furthermore,
radiological enhancement alone is a poor predictor of
malignant progression.16
Molecular drug targets in recurrent glioma
Routine testing for molecular aberrations consists of
isocitrate dehydrogenase (IDH) mutations and 1p/19q
4

codeletion in most centres, with variable access to ATRX
mutations and TP53 testing. Individual mutations are
present at a low prevalence in G2/3 gliomas; however, the
large number of potentially actionable mutations collectively result in a large proportion of patients having an
actionable mutation.17 Potential druggable genetic mutations are shown in table 3.

METHODS AND ANALYSIS
Eligibility
The inclusion and exclusion criteria for the study are
listed in box 1.
Study plan
Molecular phenotyping to generate molecular pathology report
Tumour tissue resected at surgery will undergo testing
at a single study reference laboratory using the Illumina TruSight 170 molecular screening panel, capable
of detecting the somatic mutation profile of 170 genes,
SNV, indel (151 genes), copy number abnormalities (59
genes) and gene fusion and splice variants (55 genes).18–20
The planned duration of recruitment for the study was
between 1 May 2020 and 31 May 2021.
A commercial bioinformatics pipeline (Illumina
NextSeq 550 RTA2) will be used to perform base calling
and quality scoring. Next-generation sequencing (NGS)
data analysis will be performed using a commercial
Kong BY, et al. BMJ Open 2021;11:e054075. doi:10.1136/bmjopen-2021-054075
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Box 1

Inclusion and exclusion criteria

Inclusion criteria
1. Adults aged 18 years and older, with histologically confirmed grade
2/3 glioma at initial diagnosis.
2. Prior to last craniotomy and surgery, evidence of progressive disease defined by new contrast-enhancing tumour and/or 25% increase in T2/FLAIR area compared with prior imaging after prior
treatment with radiotherapy and chemotherapy.
3. Contemporaneous tissue available from resection for progressive
disease either within 6 months of study enrolment or following
enrolment.
4. For patients undergoing standard of care surgery at the time of
study entry:
– Suitable for craniotomy in the opinion of the treating neurosurgeon.
– In the opinion of the neurosurgeon, it is possible to safely undertake a debulking procedure and sufficient tissue will be obtained
for molecular profiling.
– Has substantially recovered from surgical resection, as evidenced
by having no ongoing safety issues (e.g., postoperative infection).
5. For patients who have already undergone standard of care surgery ≤6 months prior to study entry
– Sufficient tissue must be available for molecular testing.
– The patient must not have had intervening anticancer therapy.
6. Dose at registration ≤20 mg prednisolone or ≤3 mg dexamethasone
daily (or equivalent).
7. ECOG performance status 0–2.
8. Measurable disease after last craniotomy that is suitable for repeat
assessment by MRI.
9. Willing and able to comply with all study requirements.
10. Signed, written informed consent.
Exclusion criteria
1. Glioma tissue for molecular profiling obtained ≥6 months prior to
study entry.
2. Intervening systemic therapy (chemotherapy, targeted and/or immune checkpoint inhibitors) or radiotherapy between most recent
imaging showing disease progression and study enrolment.
3. Administration of intrasurgical treatments (local therapies, carmustine wafers, focused ultrasound, oncolytic viruses, convection enhanced delivery) at last craniotomy prior to study enrolment.
4. Any serious or uncontrolled medical disorder that, in the opinion of
the investigator, may increase the risk associated with study participation or impair the ability of the subject to receive protocol therapy
or the ability of the patient to comply with the protocol.
5. Subjects unable (or unwilling) to have a contrast enhanced MRI of
the head.
6. Serious medical or psychiatric conditions that might limit the ability
of the patient to comply with the protocol.

secondary bioinformatics pipeline (Illumina’s BaseSpace
TST170 app V.1.02) for somatic variant, copy number
variant, splice variant and gene fusion analysis. This platform is not validated for assessment of tumour mutational
burden or histone mutations. A commercial tertiary bioinformatics platform (Clinical Genomics Workspace software platform from PierianDx (www.pieriandx.com) will
be used to generate quality control metrics and to identify and classify DNA/RNA alterations using databases
including but not limited to: Genomic Build GRCh37.
p13, Genomic Annotation Sources NCBI RefSeq V.105,
Kong BY, et al. BMJ Open 2021;11:e054075. doi:10.1136/bmjopen-2021-054075

Box 2

LUMOS study endpoints

Primary endpoints:
► Number of patients enrolled.
► Number of patients that successfully completed molecular

screening.
Secondary endpoints
► Proportion of screened patients enrolled.
► Proportion of patients that successfully completed molecular
screening.
► Turnaround time of molecular screening.
► Matching of molecular tumour advisory panel recommendations
with pharmaceutical agents.
► The proportion of patients in whom an MTAP recommended pharmaceutical agent is obtained and used.
► Response to any MTAP or physician-recommended pharmaceutical
agent.
► Number of patients who undergo further surgical debulking at time
of disease progression while on the study.
► The number of patients who were screened for the study.
Tertiary endpoints
► Association between clinical endpoints and predictive/prognostic
biomarkers.

NHLBI ESP V.0.0.30, dbSNP 149, COSMIC V.84, ddNSFP
3.0b2c, ClinVar 20180605, ExAC V.1.0, CGW Version
CGW_V.613.
Manual somatic variant calling by molecular scientists and molecular pathologists will then be performed
following interrogation of annotated variants using
validated quality control metrics to distinguish somatic
variants from population variants/SNPs and artefacts.
All variants will be manually reviewed in Integrative
Genome Viewer. Clinical interpretation of all DNA and
RNA variants will be performed according to guidelines
and standards for reporting somatic variant in cancer,
in accordance with a joint consensus recommendation
of the Association for Molecular Pathology, American
Society of Clinical Oncology, and the College of American Pathologists.21 Somatic variants will be classified into
a four tier system based on their clinical significance.
Tier I, variants of strong clinical significance; tier II, variants of potential clinical significance; tier III variants of
unknown clinical significance and tier IV, benign or likely
benign variants. The results will be reviewed by a molecular tumour advisory panel (MTAP) (see section 3.2.2).
The target turnaround time from receipt of tissue at the
laboratory until delivery of a molecular pathology report
is 4 weeks, chosen as an interval that will be clinically
acceptable and logistically feasible.
Molecular tumour advisory panel
Molecular aberrations that result in a potentially actionable mutation will be reviewed by an MTAP, composed
of at least one of each of the following experts: molecular pathologist, neuropathologist, medical oncologist,
translational research scientist and bioinformatician.
The MTAP will specifically refine the detailed molecular
pathology results (typically in excess of 20 pages) into
5
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a more concise 2-page format that provides: (1) expert
recommendations regarding the clinical significance of
each mutation specifically for brain tumours; (2) the
availability of corresponding targeted drugs in Australia
(either in trials or through other avenues); (3) prioritise
treatments in the presence of multiple potential actionable mutations and (4) provide graded recommendations
for potential therapies (see section 3.2.1). The MTAP
report will be provided to the patient’s treating physician,
in addition to the usual detailed molecular pathology
report generated by the reference laboratory, for their
decision on the final course of treatment.
Disclosure of clinically significant information
All participants, including those with no actionable
mutations, will be informed of the results of the MTAP
by their treating physician. Molecular screening of
tumours will predominantly generate information on
somatic mutations in tumour tissue; however, germline
pathogenic mutations may also be detected in such
material. Participants will be asked to indicate whether
they wish to receive information about hereditary cancer
risk of potential importance to their health or that of
their blood relatives. If potentially clinically significant

results are identified, the treating physician will refer the
patient to an appropriate familial genetics clinic as per
their institutional practices. No referral will be made if
the participant has chosen not to be informed of clinically significant information pertaining to hereditary
cancer risk.
Re-entry into study at progression
Patients treated with a targeted agent on study, who
then progress while on study and are still appropriate
for further surgery may have their most recent tumour
submitted for re-evaluation with the same NGS panel.
This will aim to provide preliminary data about the mechanism of resistance to the targeted agent used. Where
relevant, a second MTAP report will be generated for this
patient to guide the treating physician in selecting subsequent treatment.
Outcome measures
The outcomes measured in the LUMOS study are listed
in box 2.
Assessments will be performed according to the
schedule shown in table 4.

Table 4 Schedule of assessments for LUMOS clinical trial, showing clinical, radiological and translational assessments
Follow-up period (time from the delivery
of the MTAP report)

Molecular screening period

 

Screening and
registration
(presurgery or
within 6 months
postsurgery)

 

 

Informed consent

 
Within 14 days
prior to registration
 
X

 

 

Tissue for molecular screening

X

 

 

X (if clinically  
indicated)

Clinic assessment8

X

X1

X

X

X

Blood tests:
► Haematology: FBC with differential
► Biochemistry: EUC, LFTs & glucose

X

X1

X

X

X

Brain MRI

X

X1

X

X

X

Assessment of dexamethasone use

X

X1

X

X

X

Blood for translational research

X

1

X

 

X

X

Presurgery assessment

X

 

 

 

 

 

 

 

X
 

X
X

X
 

Determination of treating physician
Determination of current treatment
Rescreening for LUMOS

6

Delivery of
molecular
tumour
advisory panel
report

2

 

X

 
 

 
 

Follow-
up (Q 8/52
recommended
until PD on
At time of
MRI)
PD on MRI

End of
follow-up
2 years after
registration
 

Although recommended, all assessments performed after the delivery of the MTAP report are optional (1) Assessments do not need to be
repeated if within 28 days of the delivery date of the MTAP report to the treating physician. (2) The treating physician is the physician who will
be responsible for the administration of anticancer treatment to the patient where appropriate. The treating physician may be a member of the
LUMOS study team, the referring physician or some other physician as nominated by the patient.
EUC, Electrolytes, Urea and Creatinine; FBC, Full blood count; LFT, Liver function test; MTAP, molecular tumour advisory panel; PD,
Progressive disease.
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Statistical design
For this pilot study, LUMOS will use a pragmatic sample
size of 10 patients to evaluate the feasibility of this
approach.

prior to implementation, and updated on the ANZCTR
trial registry, with study investigators being advised in
writing.

Recruitment
Patients will be recruited from across five study sites
within the 12-month period of the pilot study.

DISCUSSION
To our knowledge, the LUMOS study is the first umbrella
study for relapsed G2/3 glioma in adults. It is one of
relatively few studies attempting to address the needs of
this patient population and more importantly, providing
a systematic way of testing numerous drugs for these
patients. Multiple mutations exist in the tumours of these
patients, some of which are arguably highly actionable
such as Trk fusions,22 but their low individual prevalence
makes basket design or similar studies difficult to undertake. However, the main concern about such an approach
has been the feasibility of successfully implementing such
a trial in this patient population. LUMOS aims to address
these concerns, working towards a pragmatic design for
definitive testing of targeted agents for relapsed G2/3
gliomas in the future.
LUMOS will address key questions about technical
feasibility and the speed of proposed screening techniques. One of the initial feasibility metrics we will investigate is the ability to obtain and use contemporaneous
tissue for testing. A differentiating factor of LUMOS from
other molecularly guided brain tumour studies is the use
of contemporaneous tissue to guide treatment. Data from
the GLASS consortium examining the evolution of mutations in low grade gliomas over time show that these occur
in a stochastic fashion, resulting in the need for contemporaneous tissue to guide treatment decisions.13 We will
assess whether it is safe and feasible to obtain such tissue
from patients at the time of relapse. We will also ascertain
that the tissue thus obtained can be successfully evaluated
using a common molecular panel, especially as tissue will
need to be shipped to a reference laboratory. Lastly, the
ability to provide a report in a clinically relevant time
frame will also be tested. The aspirational turnaround
time of 4 weeks in the LUMOS study (from the time of
tissue receipt at the laboratory to delivery of the MTAP
report) will be measured as a metric in this pilot study. In
a previous analysis of 40 reported studies, the mean turnaround time including molecular screening and generation of a molecular pathology report was 38.4 days but the
range was between 12.4 and 86 days; therefore, the aspirational target for LUMOS falls within these benchmarks,23
despite some heterogeneity across studies regarding the
definition of turnaround time.
We also plan to test the value of such an approach to the
referring physician and their patients. While the concept
of genomics-driven treatment recommendations is not
new, there are still many challenges to implementing
genomic information into routine cancer care. These
challenges include interpretation of complex genomic
information and limited availability of experts to provide
such recommendations21 . The LUMOS pilot study seeks
to examine these challenges within the Australian context

Statistical analysis
The following variables will be described using standard
summary statistics:
Patient recruitment:
► Number of eligible relapsed G2/3 glioma patients at
each hospital site and the study overall.
► Number and percentage of screened relapsed G2/3
glioma patients enrolled.
► Demographic and clinical characteristics of enrolled
patients.
Molecular screening metrics:
► Number and percentage of enrolled patients for
whom tissue was successfully tested.
► Reasons for not undergoing molecular screening and
for unsuccessful screening.
► Median time receipt of tissue by the reference laboratory to the time of receipt of MTAP report by the
treating physician.
► In patients in whom a molecular screening report was
received, the number of molecular targets identified
that match drugs available through clinical trials of
pharmaceutical access programmes.
► In patients in whom a target was identified, the
proportion of patients who received targeted agents
as a result of the MTAP recommendation.
Patient and public involvement
The LUMOS pilot study concept was developed in
response to the perceived unmet need for patients with
recurrent lower grade glioma, due to the paucity of clinical trials in this space. Consumers are represented on the
LUMOS trial management committee and are involved
in decisions surrounding methods for communicating
genomic information to patients in the study as well as
suggestions for future studies. Information about the
LUMOS study design will be promoted through patient
support forums.

ETHICS AND DISSEMINATION
Research ethics approval
The LUMOS study was approved by the Human Research
Ethics Committee (HREC) of (Royal Prince Alfred
Hospital Zone) of the Sydney Local Health District. HREA
(V.4, 20 November 2019), Protocol (V.1.2, 13 November
2019). Protocol No. X19-
0383 and 2019/ETH12848.
Other clinical sites provide oversight through local governance committees. Any substantial amendments to the
study protocol will be reported to the HREC for approval
Kong BY, et al. BMJ Open 2021;11:e054075. doi:10.1136/bmjopen-2021-054075
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by conducting molecular screening of patients from across
several geographically dispersed institutions and examining the feasibility of such an approach in patients with
relapsed G2/3 gliomas. We will also test the acceptability
of succinct and tumour specific reporting with participating clinicians, hoping to overcome some of the known
issues with interpretation of generic molecular pathology
reports.24 The MTAP was thus named to differentiate the
neuro-oncology expertise provided by this panel from
the tumour agnostic recommendations provided by the
bioinformatics platform matching mutations to registered trials. The instances where these recommendations
differ will be reported, thus illustrating the challenge
of not only matching mutations to treatments but also
ensuring avenues to access the treatments are communicated to treating physicians. We will also record any cases
where study participation results in patients being treated
with a targeted agent recommended by our testing and
MTAP. However, this was not included as a formal study
endpoint as we will not provide access to investigational
drug, and the lack of access to such drugs for relapsed
G2/3 patients currently makes this an unsuitable study
endpoint. However, we fully anticipate that a successful
feasibility trial would inform future such approaches.
Lastly, the LUMOS study has been designed to take
advantage of the important opportunity to collect serial
tissue in patients who have a second progression event
during the study. Such tissue will undergo repeat molecular testing if their treating physician deems the participant appropriate for a further resection. This will serve
two purposes; (1) affording the patient the potential to
find another matched treatment at disease progression
and (2) also contributing to our understanding of the
molecular evolution of these tumours over time. While
activation of genes associated with cell cycle, proliferation, invasion and tumour microenvironment are associated with progression of lower grade glioma to high
grade glioma, serial tissue from patients to demonstrate
this progression is lacking in clinical studies.25
In conclusion, LUMOS aims to establish the feasibility
of a precision oncology, umbrella trial approach for this
niche patient population with few established therapeutic
opinions. Its success will be necessary to encourage future
trials (whether from industry, academia or some combination thereof) to use a systematic approach that is arguably the only realistic way of testing drugs against a large
but heterogeneous array of potentially actionable molecular targets in this patient population.
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